Asaf Maoz, MD, on Pancreatic Surveillance Eligibility Criteria
2025 ASCO Annual Meeting
Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, discusses the sensitivity of age and family history criteria for determining eligibility for pancreatic cancer surveillance among individuals with a hereditary risk for the malignancy (Abstract 10500).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Our study looked at pancreatic cancer surveillance eligibility criteria among individuals who have a genetic risk of pancreatic cancer. Individuals who carry a pathogenic germline variant in a pancreatic cancer predisposition gene have an elevated risk of pancreatic cancer over the lifetime, and when surveillance has been done for these individuals, we have seen that this results in an earlier stage at diagnosis and improved survival compared with historical cohorts. However, not everyone who carries a pathogenic germline variant that predisposes them to pancreatic cancer has been eligible for pancreatic cancer surveillance and eligibility criteria have restricted eligibility based on age and a family history of pancreatic cancer. Our study was meant to look at the proportion of pathogenic germline variant carriers who would have been eligible for pancreatic cancer surveillance at the time of their pancreatic cancer diagnosis, and we leveraged a laboratory cohort to look at this question. We had over 11,000 individuals in the cohort and over 900 individuals who had a pathogenic germline variant that predisposes them to pancreatic cancer. Our results show that the age criteria for pancreatic cancer surveillance eligibility did very well, with over 85% of individuals who had a pathogenic germline variant and developed pancreatic cancer meeting the age eligibility criteria for surveillance. However, the family history criteria did poorly with only 22% of individuals who carry pathogenic germline variants and developing pancreatic cancer meeting the family history criteria when it's applicable. Our results suggest that having a family history of pancreatic cancer needs to be reevaluated as an eligibility criteria for pancreatic cancer surveillance among those who have a genetic risk of pancreatic cancer. We feel that our results support the recent removal of the family history requirement for pancreatic cancer surveillance eligibility for those who have germline pathogenic variants in BRCA2 and ATM.
The ASCO Post Staff
Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500).
The ASCO Post Staff
Andrew Kuykendall, MD, of Moffitt Cancer Center, discusses findings from the phase III VERIFY trial, which compared the efficacy of rusfertide vs placebo in patients with polycythemia vera who continue their current standard of care therapy (Abstract LBA3).
The ASCO Post Staff
Suneel Deepak Kamath, MD, of the Cleveland Clinic, reports findings from a study that evaluated funding from the NIH and Congressionally Directed Medical Research Programs supporting lung, breast, colorectal, pancreatic, hepatobiliary, ovarian, cervical, endometrial, and prostate cancers, as well as leukemia, lymphoma, and melanoma, from 2013 to 2022 (Abstract 11025).
The ASCO Post Staff
David Allen Barbie, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews specific clinical and molecular features of early progressors and long-term progression-free survivors from the phase III ADRIATIC trial, which assessed consolidation durvalumab vs placebo after concurrent chemoradiotherapy for limited-stage small cell lung cancer (Abstract 8014).
The ASCO Post Staff
Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon cancer (Abstract LBA3510).